Western Blotting (WB), ELISA, Immunofluorescence (IF)
Spezifität
No alternatively spliced transcript variants have been observed.
Aufreinigung
TOX Antibody is affinity chromatography purified via peptide column.
Immunogen
TOX antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human TOX. The immunogen is located within amino acids 130 - 180 of TOX.
TOX antibody can be used for detection of TOX by Western blot at 1 - 2 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
TOX Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
TOX antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
TOX
(Thymus High Mobility Group Box Protein (TOX))
TOX1 antikoerper, 1700007F02Rik antikoerper, thymocyte selection associated high mobility group box antikoerper, thymocyte selection-associated high mobility group box antikoerper, TOX antikoerper, Tox antikoerper
Hintergrund
TOX Antibody: TOX (thymocyte selection-associated high mobility group (HMG) box protein) is a member of the HMG box family of DNA-binding proteins and likely plays a role in the regulation of T-cell development. It is a 526 amino acid nuclear protein and the expression of TOX is upregulated by pre-T cell receptor (pre-TCR) and TCR activation in immature thymocytes. TOX-mediated positive selection is associated with up-regulation of RUNX3 and is calcineurin dependent. TOX-dependent transition to the CD4+CD8 stage is required for development of class II major histocompatibility complex-specific T cells.